Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | -4.91% | |
| NR7 | Range Contraction | -4.91% | |
| Wide Bands | Range Expansion | -4.91% | |
| Wide Bands | Range Expansion | -3.62% | |
| 20 DMA Resistance | Bearish | -8.58% | |
| Wide Bands | Range Expansion | -8.58% | |
| 20 DMA Resistance | Bearish | -9.36% | |
| Shooting Star Candlestick | Bearish | -9.36% | |
| Lizard Bearish | Bearish Day Trade Setup | -9.36% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -9.36% |
| Alert | Time |
|---|---|
| Down 5% | about 3 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
| Down 3% | about 5 hours ago |
| Down 2 % | about 5 hours ago |
| Down 1% | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.4 |
| Average Volume | 167,963 |
| 200-Day Moving Average | 3.52 |
| 50-Day Moving Average | 2.77 |
| 20-Day Moving Average | 2.32 |
| 10-Day Moving Average | 2.21 |
| Average True Range | 0.25 |
| RSI (14) | 40.12 |
| ADX | 29.19 |
| +DI | 13.76 |
| -DI | 21.03 |
| Chandelier Exit (Long, 3 ATRs) | 2.19 |
| Chandelier Exit (Short, 3 ATRs) | 2.70 |
| Upper Bollinger Bands | 2.78 |
| Lower Bollinger Band | 1.87 |
| Percent B (%b) | 0.41 |
| BandWidth | 38.86 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.20 |
| MACD Histogram | 0.0337 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.48 | ||||
| Resistance 3 (R3) | 2.47 | 2.39 | 2.44 | ||
| Resistance 2 (R2) | 2.39 | 2.33 | 2.39 | 2.43 | |
| Resistance 1 (R1) | 2.31 | 2.29 | 2.35 | 2.32 | 2.41 |
| Pivot Point | 2.23 | 2.23 | 2.24 | 2.23 | 2.23 |
| Support 1 (S1) | 2.15 | 2.17 | 2.19 | 2.16 | 2.07 |
| Support 2 (S2) | 2.07 | 2.13 | 2.07 | 2.05 | |
| Support 3 (S3) | 1.99 | 2.07 | 2.04 | ||
| Support 4 (S4) | 2.00 |
